INTERFERON α-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS

被引：0
|
作者：
Muir, Andrew J. [1 ]
Bacon, Bruce R. [2 ]
Gitlin, Norman [4 ]
Kugelmas, Marcelo [3 ]
Tillman, Hans L. [1 ]
Grovender, Eric A. [5 ]
Van Antwerp, Bill [5 ]
Mische, Sarah [5 ]
Kwo, Paul Y. [6 ]
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] S Denver Gastroenterol, Englewood, CO USA
[4] Atlanta Gastroenterol Associates, Atlanta, GA USA
[5] Medtronic, Ventures & New Therapies, Minneapolis, MN USA
[6] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1439A / 1439A
页数：1
相关论文
共 50 条
  • [41] Peg-interferon alfa-2b and ribavirin in treatment naive African American patients infected with HCV genotype 1.
    Stein, DF
    McKenzie, SD
    HEPATOLOGY, 2003, 38 (04) : 642A - 642A
  • [42] VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION
    Asselah, T.
    Jensen, D. M.
    Foster, G. R.
    Sulkowski, M. S.
    Ouzan, D.
    Morano, L.
    Buynak, R.
    Agarwal, K.
    Hassanein, T.
    Forton, D.
    Cho, M.
    Genne, D.
    Kaita, K.
    Maieron, A.
    Preotescu, L.
    Sarrazin, C.
    Zehnter, E.
    Streinu-Cercel, A.
    Stern, J. O.
    Datsenko, Y.
    Drulak, M.
    Voss, F.
    Quinson, A. -M.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S311 - S311
  • [43] Virological Response in Treatment-Naive Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction
    Asselah, Tarik
    Jensen, Donald M.
    Foster, Graham
    Sulkowski, Mark
    Ouzan, Denis
    Morano, Luis
    Buynak, Robert
    Agarwal, Kosh
    Hassanein, Tarek
    Forton, Daniel
    Cho, Mong
    Genne, Daniel
    Kaita, Kelly
    Maieron, Andreas
    Preotescu, Liliana
    Sarrazin, Christoph
    Zehnter, Elmar
    Streinu-Cercel, Adrian
    Stern, Jerry O.
    Datsenko, Yakov
    Drulak, Murray
    Voss, Florian
    Quinson, Anne-Marie
    Ferenci, Peter
    GASTROENTEROLOGY, 2014, 146 (05) : S975 - S976
  • [44] High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Noncirrhotic HCV GT1b-Infected Patients: An Integrated Analysis
    Serfaty, Lawrence
    Zeuzem, Stefan
    Vierling, John M.
    Howe, Anita Y.
    Hwang, Peggy
    Robertson, Michael
    Butterton, Joan R.
    Wahl, Janice
    Barr, Eliav
    Haber, Barbara A.
    HEPATOLOGY, 2015, 62 : 555A - 556A
  • [45] 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS
    Chojkier, M.
    Everson, G.
    Muir, A.
    Bacon, B.
    Rodriguez-Torres, M.
    Bennett, M.
    Fried, M.
    Gordon, S.
    Gross, J.
    Nelson, D.
    Balart, L.
    Jonas, M.
    Szabo, G.
    Bloomer, J.
    McCullough, A.
    Nyberg, L.
    Smith, C.
    Bohm, O.
    Fox, A. W.
    Castelloe, E.
    Huyghe, M.
    Mento, S.
    Spada, A.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S165 - S165
  • [46] Twenty-four weeks of interferon α-2b in combination with ribavirin for Japanese hepatitis C patients:: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1
    Fujiwara, Keiichi
    Yokosuka, Osamu
    Komine, Fumihiko
    Moriyama, Mitsuhiko
    Kato, Naoya
    Yoshida, Haruhiko
    Tanaka, Naohide
    Imazeki, Fumio
    Shiratori, Yasushi
    Arakawa, Yasuyuki
    Omata, Masao
    LIVER INTERNATIONAL, 2006, 26 (05) : 520 - 528
  • [47] Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection
    Zeuzem, S.
    Benhamou, Y.
    Shouval, D.
    Bain, V.
    Pianko, S.
    Flisiak, R.
    Grigorescu, M.
    Rehak, V.
    Yoshida, E.
    Kaitalo, K.
    Hezode, C.
    Neumann, A. U.
    Subramanian, M.
    McHutchison, J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S270 - S270
  • [48] Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C - Relapsed and treatment-naive patients
    Maddrey, WC
    SEMINARS IN LIVER DISEASE, 1999, 19 : 67 - 75
  • [49] Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
    Everson, Gregory T.
    Sims, Karen D.
    Rodriguez-Torres, Maribel
    Hezode, Christophe
    Lawitz, Eric
    Bourliere, Marc
    Loustaud-Ratti, Veronique
    Rustgi, Vinod
    Schwartz, Howard
    Tatum, Harvey
    Marcellin, Patrick
    Pol, Stanislas
    Thuluvath, Paul J.
    Eley, Timothy
    Wang, Xiaodong
    Huang, Shu-Pang
    McPhee, Fiona
    Wind-Rotolo, Megan
    Chung, Ellen
    Pasquinelli, Claudio
    Grasela, Dennis M.
    Gardiner, David F.
    GASTROENTEROLOGY, 2014, 146 (02) : 420 - 429
  • [50] Safety, tolerability and efficacy of Interferon alfa 2b and Ribavirin combination therapy in HCV patients with cirrhosis
    Ravinuthala, R
    Pai, V
    Moonka, D
    Brown, K
    GASTROENTEROLOGY, 2003, 124 (04) : A383 - A383
12345